3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
3
Mesothelioma
3
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Medical Oncology
1
Fallopian Tube Endometrioid Adenocarcinoma
1
Cholangiocarcinoma
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
44
pembrolizumab
34
Fluorouracil
32
Capecitabine
30
durvalumab
27
Leucovorin
26
lenvatinib
23
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Platinum
8
Folfox protocol
8
Carboplatin
8
1,2-diaminocyclohexaneplatinum II citrate
8
tremelimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled